TransMedics Ushers In New CFO, Tightens 2024 Revenue Goals
TransMedics Ushers In New CFO, Tightens 2024 Revenue Goals
Moreover, the company also tweaked its financial outlook for 2024 and now expects revenue in the range of $428 million – $432 million versus the consensus of $432.36 million.TransMedics Group, Inc. (NASDAQ:TMDX) shares are trading lower premarket on Tuesday. On Monday, the company announced the appointment of Gerardo Hernandez as Chief Financial Officer, effective December 2, 2024.
transmedics集團公司（納斯達克：TMDX）在週二的盤前交易中，股價下跌。週一，該公司宣佈任命Gerardo Hernandez爲首席財務官，任職時間爲2024年12月2日生效。
Gerardo Hernandez will be succeeding Stephen Gordon, who will remain with the company as a non-executive employee until March 31, 2025, to ensure a seamless transition.
Gerardo Hernandez將接替Stephen Gordon，後者將在公司擔任非執行員工，直至2025年3月31日，以確保順利過渡。
Waleed Hassanein, M.D., President and Chief Executive Officer, commented, "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer. His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team."
Waleed Hassanein萬.D.，總裁兼首席執行官，評論道：「我很高興歡迎Gerardo加入transmedics領導團隊，成爲我們的新首席財務官。他在過去二十年中在高增長、複雜的全球組織中，領導FP&A職能的卓越記錄，使他成爲我們團隊的理想補充。」
Moreover, the company also tweaked its financial outlook for 2024 and now expects revenue in the range of $428 million – $432 million versus the consensus of $432.36 million.
此外，該公司還調整了2024年的財務展望，現在預計營業收入在$42800萬 – $43200萬之間，而市場共識爲$43236萬。
This compares with a prior view of $425 million – $445 million.
與之前的預期$42500萬 – $44500萬相比。
In October, the company reported a third-quarter EPS of $0.12, missing the consensus of $0.30, and sales of $108.8 million, up 64% year over year, but missing the consensus of $115 million.
在十月份，該公司公佈了第三季度每股收益爲$0.12，未達到市場共識的$0.30，銷售額爲$10880萬，同比增長64%，但未達到市場共識的$11500萬。
At that time, the company said that they are on track to reach the target of achieving 10,000 OCS transplant cases per year in the U.S. by 2028.
當時，該公司表示他們正朝着到2028年在美國實現每年10000個OCS移植病例的目標邁進。
TransMedics plans to host the Investor & Analyst Day on December 10, 2024.
transmedics計劃於2024年12月10日舉辦投資者及分析師日。
Price Action: TMDX shares are down 8.37% at $78.01 premarket at the last check Tuesday.
價格走勢：在最後一次檢查時，TMDX的股票在週二的盤前交易中下跌了8.37%，價格爲78.01美元。
Read Next:
閱讀下一篇：
- Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
- 摩根士丹利儘管面臨2024年的一些挫折，依舊維持對醫療科技的積極展望，升級了直覺外科公司和斯特萊克，降低了對nevro和glaukos的評級。
譯文內容由第三人軟體翻譯。
